<italic style="font-style: italic">BRAF</italic> V600突变阳性的晚期黑色素瘤治疗的临床研究进展

江健韵; 应红梅

doi:10.19401/j.cnki.1007-3639.2022.05.010

您当前的位置：

首页 >

文章列表页 >

BRAF V600突变阳性的晚期黑色素瘤治疗的临床研究进展

综述 | 更新时间：2025-12-31

- BRAF V600突变阳性的晚期黑色素瘤治疗的临床研究进展
- Clinical research progress in the treatment of BRAF V600 mutation-positive advanced melanoma
- 中国癌症杂志 2022年32卷第5期页码：445-450
- 作者机构：
  
  1. 复旦大学附属肿瘤医院放射治疗中心,复旦大学上海医学院肿瘤学系,上海 200032
  2. 上海市放射肿瘤学重点实验室,上海 200032
- 作者简介：
  
  [ "江健韵（ORCID: 0000-0002-3137-8597）,学士 E-mail: jjy2019531@163.com" ]
  应红梅（ORCID: 0000-0003-2642-3135）;博士,主任医师,复旦大学附属肿瘤医院放疗中心头颈专科主任E-mail: yinghm@hotmail.com
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.05.010
  中图分类号： R739.5
- 收稿：2022-01-29，
  
  修回：2022-05-11，
  
  纸质出版：2022-05-30
- 稿件说明：
移动端阅览
江健韵, 应红梅. BRAF V600突变阳性的晚期黑色素瘤治疗的临床研究进展[J]. 中国癌症杂志, 2022,32(5):445-450.

Jianyun JIANG, Hongmei YING. Clinical research progress in the treatment of BRAF V600 mutation-positive advanced melanoma[J]. China Oncology, 2022, 32(5): 445-450.
江健韵, 应红梅. BRAF V600突变阳性的晚期黑色素瘤治疗的临床研究进展[J]. 中国癌症杂志, 2022,32(5):445-450. DOI： 10.19401/j.cnki.1007-3639.2022.05.010.

Jianyun JIANG, Hongmei YING. Clinical research progress in the treatment of BRAF V600 mutation-positive advanced melanoma[J]. China Oncology, 2022, 32(5): 445-450. DOI： 10.19401/j.cnki.1007-3639.2022.05.010.

摘要

多数黑色素瘤具有

BRAF

V600E/K突变

因此V600成为黑色素瘤精准治疗的重要靶点

并通常可被BRAF抑制剂和MEK抑制剂联合阻断。免疫检查点抑制剂的出现也极大地改善了

BRAF

V600突变阳性的晚期黑色素瘤患者的治疗结局

探究这部分患者的最佳一线治疗及序贯治疗顺序的临床试验正在开展。本文就精准医疗时代

BRAF

V600突变阳性的晚期黑色素瘤患者治疗的最新研究进展进行综述。

Abstract

Most melanomas have

BRAF

V600E/K mutations

making V600 an important target for precision treatment of melanoma

and it can often be blocked by a combination of BRAF inhibitors and MEK inhibitors. The emergence of immune checkpoint inhibitors has also greatly improved the treatment outcome of patients with

BRAF

V600 mutation-positive advanced melanoma. Clinical trials are also underway to determine the best first-line treatment and the sequence of combination therapies for these patients. This paper reviewed the latest progress in the treatment of

BRAF

V600 mutation-positive advanced melanoma in the era of precision medicine.

关键词

Keywords

references

MICHIELIN O , VAN AKKOOI A C J , ASCIERTO P A , et al . Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † [J ] . Ann Oncol , 2019 , 30 ( 12 ): 1884 - 1901 . DOI: 10.1093/annonc/mdz411 http://doi.org/10.1093/annonc/mdz411 https://linkinghub.elsevier.com/retrieve/pii/S0923753420325631 https://linkinghub.elsevier.com/retrieve/pii/S0923753420325631

RICHTIG G , HOELLER C , KASHOFER K , et al . Beyond the BRAF V600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients [J ] . Br J Dermatol , 2017 , 177 ( 4 ): 936 - 944 . DOI: 10.1111/bjd.15436 http://doi.org/10.1111/bjd.15436 https://onlinelibrary.wiley.com/doi/10.1111/bjd.15436 https://onlinelibrary.wiley.com/doi/10.1111/bjd.15436

HAUSCHILD A , ASCIERTO P A , SCHADENDORF D , et al . Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: analysis from phase 2 and 3 clinical trials [J ] . Eur J Cancer , 2020 , 125 : 114 - 120 . DOI: 10.1016/j.ejca.2019.10.033 http://doi.org/10.1016/j.ejca.2019.10.033 https://linkinghub.elsevier.com/retrieve/pii/S0959804919308159 https://linkinghub.elsevier.com/retrieve/pii/S0959804919308159

ROBERT C , FLAHERTY K , NATHAN P , et al . Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600E/K-mutant advanced or metastatic melanoma [J ] . Eur J Cancer , 2019 , 109 : 61 - 69 . DOI: 10.1016/j.ejca.2018.12.015 http://doi.org/10.1016/j.ejca.2018.12.015 https://linkinghub.elsevier.com/retrieve/pii/S0959804918315612 https://linkinghub.elsevier.com/retrieve/pii/S0959804918315612

SIMEONE E , GRIMALDI A M , FESTINO L , et al . Combination treatment of patients with BRAF -mutant melanoma: a new standard of care [J ] . BioDrugs , 2017 , 31 ( 1 ): 51 - 61 . DOI: 10.1007/s40259-016-0208-z http://doi.org/10.1007/s40259-016-0208-z http://link.springer.com/10.1007/s40259-016-0208-z http://link.springer.com/10.1007/s40259-016-0208-z

WOLCHOK J D , KLUGER H , CALLAHAN M K , et al . Nivolumab plus ipilimumab in advanced melanoma [J ] . N Engl J Med , 2013 , 369 ( 2 ): 122 - 133 . DOI: 10.1056/NEJMoa1302369 http://doi.org/10.1056/NEJMoa1302369 http://www.nejm.org/doi/10.1056/NEJMoa1302369 http://www.nejm.org/doi/10.1056/NEJMoa1302369

LARKIN J , CHIARION-SILENI V , GONZALEZ R , et al . Five-year survival with combined nivolumab and ipilimumab in advanced melanoma [J ] . N Engl J Med , 2019 , 381 ( 16 ): 1535 - 1546 . DOI: 10.1056/NEJMoa1910836 http://doi.org/10.1056/NEJMoa1910836 http://www.nejm.org/doi/10.1056/NEJMoa1910836 http://www.nejm.org/doi/10.1056/NEJMoa1910836

WOLCHOK J D , CHIARION-SILENI V , GONZALEZ R , et al . Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma [J ] . J Clin Oncol , 2022 , 40 ( 2 ): 127 - 137 .

LUKE J J , FLAHERTY K T , RIBAS A , et al . Targeted agents and immunotherapies: optimizing outcomes in melanoma [J ] . Nat Rev Clin Oncol , 2017 , 14 ( 8 ): 463 - 482 . DOI: 10.1038/nrclinonc.2017.43 http://doi.org/10.1038/nrclinonc.2017.43 https://www.nature.com/articles/nrclinonc.2017.43 https://www.nature.com/articles/nrclinonc.2017.43

EGGERMONT A M M , BLANK C U , MANDALA M , et al . Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage Ⅲ melanoma: updated results from the EORTC 1325-MG/KEYNOTE-054 trial [J ] . J Clin Oncol , 2020 , 38 ( 33 ): 3925 - 3936 . DOI: 10.1200/JCO.20.02110 http://doi.org/10.1200/JCO.20.02110 https://ascopubs.org/doi/10.1200/JCO.20.02110 https://ascopubs.org/doi/10.1200/JCO.20.02110

LONG G V , HAUSCHILD A , SANTINAMI M , et al . Adjuvant dabrafenib plus trametinib in stage & #x02162; BRAF -mutated melanoma [J ] . N Engl J Med , 2017 , 377 ( 19 ): 1813 - 1823 . DOI: 10.1056/NEJMoa1708539 http://doi.org/10.1056/NEJMoa1708539 http://www.nejm.org/doi/10.1056/NEJMoa1708539 http://www.nejm.org/doi/10.1056/NEJMoa1708539

ASCIERTO P A , DRÉNO B , LARKIN J , et al . 5-year outcomes with cobimetinib plus vemurafenib in BRAF V600 mutation-positive advanced melanoma: extended follow-up of the coBRIM study [J ] . Clin Cancer Res , 2021 , 27 ( 19 ): 5225 - 5235 . DOI: 10.1158/1078-0432.CCR-21-0809 http://doi.org/10.1158/1078-0432.CCR-21-0809 https://aacrjournals.org/clincancerres/article/27/19/5225/671702/5-Year-Outcomes-with-Cobimetinib-plus-Vemurafenib https://aacrjournals.org/clincancerres/article/27/19/5225/671702/5-Year-Outcomes-with-Cobimetinib-plus-Vemurafenib

GUTZMER R , STROYAKOVSKIY D , GOGAS H , et al . Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial [J ] . Lancet , 2020 , 395 ( 10240 ): 1835 - 1844 . DOI: 10.1016/S0140-6736(20)30934-X http://doi.org/10.1016/S0140-6736(20)30934-X https://linkinghub.elsevier.com/retrieve/pii/S014067362030934X https://linkinghub.elsevier.com/retrieve/pii/S014067362030934X

ROBERT C , GROB J J , STROYAKOVSKIY D , et al . Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma [J ] . N Engl J Med , 2019 , 381 ( 7 ): 626 - 636 . DOI: 10.1056/NEJMoa1904059 http://doi.org/10.1056/NEJMoa1904059 http://www.nejm.org/doi/10.1056/NEJMoa1904059 http://www.nejm.org/doi/10.1056/NEJMoa1904059

DUMMER R , LONG G V , ROBERT C , et al . Randomized phase & #x02162; trial evaluating spartalizumab plus dabrafenib and trametinib for BRAF V600-mutant unresectable or metastatic melanoma [J ] . J Clin Oncol , 2022 , 40 ( 13 ): 1428 - 1438 . DOI: 10.1200/JCO.21.01601 http://doi.org/10.1200/JCO.21.01601 https://ascopubs.org/doi/10.1200/JCO.21.01601 https://ascopubs.org/doi/10.1200/JCO.21.01601

RIBAS A , DAUD A , PAVLICK A C , et al . Extended 5-year follow-up results of a phase & #x02160;b study (BRIM7) of vemurafenib and cobimetinib in BRAF -mutant melanoma [J ] . Clin Cancer Res , 2020 , 26 ( 1 ): 46 - 53 . DOI: 10.1158/1078-0432.CCR-18-4180 http://doi.org/10.1158/1078-0432.CCR-18-4180 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-18-4180 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-18-4180

LONG G V , EROGLU Z , INFANTE J , et al . Long-term outcomes in patients with BRAF V600-mutant metastati c melanoma who received dabrafenib combined with trametinib [J ] . J Clin Oncol , 2018 , 36 ( 7 ): 667 - 673 .

LARKIN J , HODI F S , WOLCHOK J D . Combined nivolumab and ipilimumab or monotherapy in untreated melanoma [J ] . N Engl J Med , 2015 , 373 ( 13 ): 1270 - 1271 . DOI: 10.1056/NEJMc1509660 http://doi.org/10.1056/NEJMc1509660 http://www.nejm.org/doi/10.1056/NEJMc1509660 http://www.nejm.org/doi/10.1056/NEJMc1509660

WOLCHOK J D , CHIARION-SILENI V , GONZALEZ R , et al . Overall survival with combined nivolumab and ipilimumab in advanced melanoma [J ] . N Engl J Med , 2017 , 377 ( 14 ): 1345 - 1356 . DOI: 10.1056/NEJMoa1709684 http://doi.org/10.1056/NEJMoa1709684 http://www.nejm.org/doi/10.1056/NEJMoa1709684 http://www.nejm.org/doi/10.1056/NEJMoa1709684

HODI F S , CHIARION-SILENI V , GONZALEZ R , et al . Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial [J ] . Lancet Oncol , 2018 , 19 ( 11 ): 1480 - 1492 . DOI: 10.1016/S1470-2045(18)30700-9 http://doi.org/10.1016/S1470-2045(18)30700-9 https://linkinghub.elsevier.com/retrieve/pii/S1470204518307009 https://linkinghub.elsevier.com/retrieve/pii/S1470204518307009

FREDERICK D T , PIRIS A , COGDILL A P , et al . BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma [J ] . Clin Cancer Res , 2013 , 19 ( 5 ): 1225 - 1231 . DOI: 10.1158/1078-0432.CCR-12-1630 http://doi.org/10.1158/1078-0432.CCR-12-1630 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-12-1630 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-12-1630

HU-LIESKOVAN S , MOK S , HOMET MORENO B , et al . Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF (V600E) melanoma [J ] . Sci Transl Med , 2015 , 7 ( 279 ): 279ra41 .

HU-LIESKOVAN S , ROBERT L , HOMET MORENO B , et al . Combining targeted therapy with immunotherapy in BRAF -mutant melanoma: promise and challenges [J ] . J Clin Oncol , 2014 , 32 ( 21 ): 2248 - 2254 . DOI: 10.1200/JCO.2013.52.1377 http://doi.org/10.1200/JCO.2013.52.1377 https://ascopubs.org/doi/10.1200/JCO.2013.52.1377 https://ascopubs.org/doi/10.1200/JCO.2013.52.1377

RIBAS A , HODI F S , CALLAHAN M , et al . Hepatotoxicity with combination of vemurafenib and ipilimumab [J ] . N Engl J Med , 2013 , 368 ( 14 ): 1365 - 1366 . DOI: 10.1056/NEJMc1302338 http://doi.org/10.1056/NEJMc1302338 http://www.nejm.org/doi/10.1056/NEJMc1302338 http://www.nejm.org/doi/10.1056/NEJMc1302338

MINOR D R , PUZANOV I , CALLAHAN M K , et al . Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab [J ] . Pigment Cell Melanoma Res , 2015 , 28 ( 5 ): 611 - 612 . DOI: 10.1111/pcmr.12383 http://doi.org/10.1111/pcmr.12383 https://onlinelibrary.wiley.com/doi/10.1111/pcmr.12383 https://onlinelibrary.wiley.com/doi/10.1111/pcmr.12383

FERRUCCI P F , DI GIACOMO A M , DEL VECCHIO M , et al . KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in -mutant melanoma [J ] . Jr Immunother Cancer , 2020 , 8 ( 2 ): 66 - 68 .

ASCIERTO P A , MANDALA M , FERRUCCI P F , et al . LBA40 SECOMBIT: The best sequential approach with combo immunotherapy[ipilimumab (I)/nivolumab (N) ] and combo target therapy[encorafenib (E)/binimetinib (B) ] in patients with BRAF mutated metastatic melanoma: a phase & #x02161; randomized study [J ] . Ann Oncol , 2021 , 32 : S1316 - S1317 . DOI: 10.1016/j.annonc.2021.08.2118 http://doi.org/10.1016/j.annonc.2021.08.2118 https://linkinghub.elsevier.com/retrieve/pii/S0923753421044227 https://linkinghub.elsevier.com/retrieve/pii/S0923753421044227

ASCIERTO P A , MANDALA M , FERRUCCI P F , et al . LBA45 first report of efficacy and safety from the phase Ⅱ study SECOMBIT (SEquential COMBo immuno and targeted therapy study) [J ] . Ann Oncol , 2020 , 31 : S1173 - S1174 .

JOSEPH R W , ELASSAISS-SCHAAP J , KEFFORD R , et al . Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab [J ] . Clin Cancer Res , 2018 , 24 ( 20 ): 4960 - 4967 . DOI: 10.1158/1078-0432.CCR-17-2386 http://doi.org/10.1158/1078-0432.CCR-17-2386 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-17-2386 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-17-2386

WARNER A B , POSTOW M A . Bigger is not always better: tumor size and prognosis in advanced melanoma [J ] . Clin Cancer Res , 2018 , 24 ( 20 ): 4915 - 4917 . DOI: 10.1158/1078-0432.CCR-18-1311 http://doi.org/10.1158/1078-0432.CCR-18-1311 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-18-1311 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-18-1311

DAUD A I , WOLCHOK J D , ROBERT C , et al . Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma [J ] . J Clin Oncol , 2016 , 34 ( 34 ): 4102 - 4109 . DOI: 10.1200/JCO.2016.67.2477 http://doi.org/10.1200/JCO.2016.67.2477 https://ascopubs.org/doi/10.1200/JCO.2016.67.2477 https://ascopubs.org/doi/10.1200/JCO.2016.67.2477

CARLINO M S , LONG G V , SCHADENDORF D , et al . Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: a randomised clinical trial [J ] . Eur J Cancer , 2018 , 101 : 236 - 243 . DOI: 10.1016/j.ejca.2018.06.034 http://doi.org/10.1016/j.ejca.2018.06.034 https://linkinghub.elsevier.com/retrieve/pii/S0959804918309481 https://linkinghub.elsevier.com/retrieve/pii/S0959804918309481

CLEMENTE C G , MIHM M C Jr , BUFALINO R , et al . Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma [J ] . Cancer , 1996 , 77 ( 7 ): 1303 - 1310 . DOI: 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5 http://doi.org/10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5 https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5 https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5

TRUJILLO J A , SWEIS R F , BAO R Y , et al . Tcell-inflamed versus non-T cell-inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection [J ] . Cancer Immunol Res , 2018 , 6 ( 9 ): 990 - 1000 . DOI: 10.1158/2326-6066.CIR-18-0277 http://doi.org/10.1158/2326-6066.CIR-18-0277 http://cancerimmunolres.aacrjournals.org/lookup/doi/10.1158/2326-6066.CIR-18-0277 http://cancerimmunolres.aacrjournals.org/lookup/doi/10.1158/2326-6066.CIR-18-0277

AYERS M , LUNCEFORD J , NEBOZHYN M , et al . IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade [J ] . J Clin Investig , 2017 , 127 ( 8 ): 2930 - 2940 . DOI: 10.1172/JCI91190 http://doi.org/10.1172/JCI91190 https://www.jci.org/articles/view/91190 https://www.jci.org/articles/view/91190

BAO R Y , STAPOR D , LUKE J J . Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types [J ] . Genome Med , 2020 , 12 ( 1 ): 90 . DOI: 10.1186/s13073-020-00787-6 http://doi.org/10.1186/s13073-020-00787-6 https://doi.org/10.1186/s13073-020-00787-6 https://doi.org/10.1186/s13073-020-00787-6

NG S B , BIGHAM A W , BUCKINGHAM K J , et al . Exome sequencing identifies MLL 2 mutations as a cause of Kabuki syndrome [J ] . Nat Genet , 2010 , 42 ( 9 ): 790 - 793 . DOI: 10.1038/ng.646 http://doi.org/10.1038/ng.646 https://doi.org/10.1038/ng.646 https://doi.org/10.1038/ng.646

LI X , ZHANG Q , SHI Q Z , et al . Demethylase Kdm6a epigenetically promotes IL-6 and IFN-β production in macrophages [J ] . J Autoimmun , 2017 , 80 : 85 - 94 . DOI: 10.1016/j.jaut.2017.02.007 http://doi.org/10.1016/j.jaut.2017.02.007 https://linkinghub.elsevier.com/retrieve/pii/S0896841116303602 https://linkinghub.elsevier.com/retrieve/pii/S0896841116303602

CRISTESCU R , MOGG R , AYERS M , et al . Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy [J ] . Science , 2018 , 362 ( 6411 ): eaar3593 . DOI: 10.1126/science.aar3593 http://doi.org/10.1126/science.aar3593 https://www.science.org/doi/10.1126/science.aar3593 https://www.science.org/doi/10.1126/science.aar3593

CHAKRABORTY A A , LAUKKA T , MYLLYKOSKI M , et al . Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate [J ] . Science , 2019 , 363 ( 6432 ): 1217 - 1222 . DOI: 10.1126/science.aaw1026 http://doi.org/10.1126/science.aaw1026 https://www.science.org/doi/10.1126/science.aaw1026 https://www.science.org/doi/10.1126/science.aaw1026

WCULEK S K , CUETO F J , MUJAL A M , et al . Dendritic cells in cancer immunology and immunotherapy [J ] . Nat Rev Immunol , 2020 , 20 ( 1 ): 7 - 24 . DOI: 10.1038/s41577-019-0210-z http://doi.org/10.1038/s41577-019-0210-z https://doi.org/10.1038/s41577-019-0210-z https://doi.org/10.1038/s41577-019-0210-z

WEISSMANN S , CLOOS P A , SIDOLI S , et al . The tumor suppressor CIC directly regulates MAPK pathway genes via histone deacetylation [J ] . Cancer Res , 2018 , 78 ( 15 ): 4114 - 4125 . DOI: 10.1158/0008-5472.CAN-18-0342 http://doi.org/10.1158/0008-5472.CAN-18-0342 http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-18-0342 http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-18-0342

LONG G V , GROB J J , NATHAN P , et al . Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials [J ] . Lancet Oncol , 2016 , 17 ( 12 ): 1743 - 1754 . DOI: 10.1016/S1470-2045(16)30578-2 http://doi.org/10.1016/S1470-2045(16)30578-2 https://linkinghub.elsevier.com/retrieve/pii/S1470204516305782 https://linkinghub.elsevier.com/retrieve/pii/S1470204516305782

ASCIERTO P A , ROBERT C , LEWIS K , et al . 1102P Clinical benefit in BRAF V600 mutation-positive melanoma defined by programmed death ligand 1 (PD-L1) and/or lactate dehydrogenase (LDH) status: exploratory analyses from the IMspire150 study [J ] . Ann Oncol , 2020 , 31 : S745 .

RUOCCO M R , AVAGLIANO A , GRANATO G , et al . Metabolic flexibility in melanoma: a potential therapeutic target [J ] . Semin Cancer Biol , 2019 , 59 : 187 - 207 . DOI: 10.1016/j.semcancer.2019.07.016 http://doi.org/10.1016/j.semcancer.2019.07.016 https://linkinghub.elsevier.com/retrieve/pii/S1044579X19300045 https://linkinghub.elsevier.com/retrieve/pii/S1044579X19300045

浏览量

1422

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

免疫相关不良事件中糖皮质激素及免疫抑制剂管理策略对患者生存结局的影响：系统评价与Meta分析

抗EGFR单抗联合免疫检查点抑制剂治疗头颈部鳞状细胞癌专家共识（2025年版）

免疫检查点抑制剂治疗相关胸腔积液的研究进展

复发/转移性头颈部鳞癌免疫检查点抑制剂治疗专家共识（2024年版）

托法替布治疗激素抵抗型免疫检查点抑制剂相关心肌炎的临床研究

BRAF V600突变阳性的晚期黑色素瘤治疗的临床研究进展

Clinical research progress in the treatment of BRAF V600 mutation-positive advanced melanoma

DOI：10.19401/j.cnki.1007-3639.2022.05.010

摘要

Abstract

关键词

Keywords

references